Tom Sheperd named Chief Executive Officer of the BIOASTER Technology Research Institute
The Board of Directors of BIOASTER, the Technology Research Institute focused on infectious diseases and microbiology, announced the appointment of Dr. Tom Shepherd as Chief Executive Officer.
He succeeds Jacques Berger who, following his retirement from his previous position as Directeur Général Délégué of Sanofi Pasteur, had been asked to set up BIOASTER’s corporate and laboratory operations and establish the foundations for its future growth into a leading research institute.
Dr. Shepherd is a British citizen and, following his Ph.D. in Biochemistry obtained in Scotland, has committed over thirty years to life science research, development and commercialization, primarily in the pharmaceutical and biotechnology industries. He has extensive international experience having built and led corporate, business and R&D teams in four continents.
He has held CEO positions with CXR Biosciences and Vascular Flow Technologies in Scotland and with Neurotech S.A. in Paris and Rhode Island, USA, as well as Head of Business Development responsibilities at Kymab Ltd. in Cambridge, UK, Intrabiotics Pharmaceuticals and ICN (Valeant) Pharmaceuticals in California and various executive positions in marketing and R&D in the UK, Australia and South Korea.
Most read news
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.